Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a licensing and option agreement with Viral Vector ...
Oxford, UK – 2 June 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, will today host a Capital Markets Event for equity research analysts and institutional ...
New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end ...
Oxford, UK - 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & ...
Explore the LON:OXB financials. Find the Oxford BioMedica financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key ...
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy market Event to highlight OXB’s proven track record, leading technical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results